Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

2 weeks ago 10

Jonathan Ponciano, The Motley Fool

Sun, February 22, 2026 astatine 12:32 PM CST 4 min read

On February 17, 2026, Redmile Group disclosed a bargain of 4,415,514 Nurix Therapeutics (NASDAQ:NRIX) shares, an estimated $63.43 cardinal commercialized based connected quarterly mean pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Redmile Group bought 4,415,514 further shares of Nurix Therapeutics (NASDAQ:NRIX). The estimated transaction worth was $63.43 million, calculated utilizing the mean unadjusted adjacent for the 4th fourth of 2025. At quarter-end, the worth of Redmile’s Nurix Therapeutics presumption accrued by $119.55 million, a fig that incorporates some caller stock purchases and changes successful the banal price.

Redmile Group's Nurix Therapeutics presumption present represents 11.31% of its $1.358 cardinal successful 13F reportable AUM pursuing the buy.
Top 5 holdings aft the filing:
- NASDAQ:SRRK: $229.98 cardinal (16.9% of AUM)
- NASDAQ:KRYS: $167.08 cardinal (12.3% of AUM)
- NASDAQ:NRIX: $153.54 cardinal (11.3% of AUM)
- NASDAQ:STOK: $128.04 cardinal (9.4% of AUM)
- NASDAQ:IMNM: $122.83 cardinal (9.0% of AUM)
As of February 17, 2026, shares of Nurix Therapeutics were priced astatine $15.64, down 6.52% implicit the anterior twelvemonth and underperforming the S&P 500 by 23.00 percent points.

Metric

Value

Price (as of marketplace adjacent 2/17/26)	$15.64
Market Capitalization	$1.37 billion
Revenue (TTM)	$83.98 million
Net Income (TTM)	($264.46 million)

Nurix Therapeutics develops tiny molecule therapies targeting crab and immune disorders, with pb programs including BTK degraders (NX-2127, NX-5948) and CBL-B inhibitors (NX-1607, NX-0255).
The institution operates a research-driven biopharmaceutical model, generating gross done merchandise candidates successful objective trials and strategical collaborations with firms specified arsenic Gilead Sciences and Sanofi.
It serves oncology and immunology markets, focusing connected patients with relapsed oregon refractory cancers and autoimmune diseases.

Nurix Therapeutics, Inc. is simply a biotechnology institution leveraging targeted macromolecule modulation to code unmet needs successful oncology and immune disorders. The institution pursues a pipeline of innovative therapies and partners with large pharmaceutical firms to beforehand its objective programs. Its strategical collaborations and proprietary level presumption it to vie successful the rapidly evolving biopharmaceutical landscape.

Nurix is not a momentum darling astatine the moment. The banal is down implicit the past twelvemonth and trails the broader market. Yet the institution conscionable moved its pb BTK degrader, bexobrutideg, into a registrational DAYBreak program, supported by Phase 1 information showing an 83% nonsubjective effect complaint and median progression-free endurance of 22.1 months. The firm’s CEO described past 4th arsenic “a pivotal inflection point” for the firm.

Financially, Nurix ended fiscal 2025 with $592.9 cardinal successful currency and marketable securities, bolstered by a $250 cardinal equity offering successful October. Revenue for the twelvemonth reached $84 million, though R&D spending climbed to $316.9 cardinal arsenic the institution accelerated objective programs. Meanwhile, the nett nonaccomplishment widened to $264.5 million, showing that this is simply a capital-intensive communicative by design.

With Nurix astatine much than 11% of assets, it sits alongside different high-conviction biotech bets. For semipermanent investors, the question is simple. Do you judge degrader-based medicines tin reset standards successful CLL and beyond? If the pivotal information deliver, today’s volatility volition look similar array stakes.

Read Entire Article